Takeda

A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes

Phase 2Recruiting42 people6 Jan 2026clinicaltrials.gov

NCT07224100

CollaboratorPhase 2Recruiting33 people4 Nov 2025clinicaltrials.gov

NCT06831370

Phase 4Recruiting124 people18 Feb 2025clinicaltrials.gov

NCT06793943

Phase 1Completed78 people27 Jan 2025clinicaltrials.gov

NCT05673785

Phase 2Active, not recruiting52 people6 Jan 2023clinicaltrials.gov

NCT05183139

Phase 4Withdrawn0 people10 Jan 2022clinicaltrials.gov

NCT05070247

Phase 1/2Terminated61 people7 Oct 2021clinicaltrials.gov

NCT04685616

CollaboratorPhase 3Recruiting1,042 people28 Dec 2020clinicaltrials.gov

NCT04536298

CollaboratorPhase 3Completed2,024 people2 Sept 2020clinicaltrials.gov

NCT04272775

Phase 1Terminated14 people17 Feb 2020clinicaltrials.gov

NCT04129502

Phase 3Active, not recruiting354 people16 Oct 2019clinicaltrials.gov

NCT04094961

CollaboratorPhase 1/2Active, not recruiting52 people19 Sept 2019clinicaltrials.gov

NCT04009109

CollaboratorPhase 2Active, not recruiting79 people5 Jul 2019clinicaltrials.gov

NCT03984097

Phase 1Completed50 people12 Jun 2019clinicaltrials.gov

NCT03942224

CollaboratorPhase 2Status unknown49 people8 May 2019clinicaltrials.gov

NCT03817320

CollaboratorPhase 1/2Active, not recruiting24 people25 Jan 2019clinicaltrials.gov

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

CollaboratorPhase 2Active, not recruiting40 people4 Dec 2018clinicaltrials.gov

NCT03746652

CollaboratorPhase 2Status unknown50 people20 Nov 2018clinicaltrials.gov

NCT03732703

CollaboratorPhase 1/2Completed103 people7 Nov 2018clinicaltrials.gov

NCT03683277

CollaboratorPhase 2Terminated26 people25 Sept 2018clinicaltrials.gov